Ichnos Sciences, Inc.
Please contact Sales at: (212) 520-2765 or email PharmaNewsSales@informa.com
Latest From Ichnos Sciences, Inc.
Glenmark’s spin-out innovation arm, Ichnos, faces a crucial year of effort to partner out certain potential first-in-class therapeutics for autoimmune diseases and also to advance its oncology pipeline. Meanwhile, CEO and ex-Gilead executive Alessandro Riva is moving on.
Amgen said Phase II data are planned for the EADV 2021 meeting, but KHK4083 will need a strong showing.
- Other Names / Subsidiaries
- Glenmark Pharmaceuticals Limited